WHY ADD A

VISCOSUPPLEMENTATION
PRODUCT FOR OSTEOARTHRITIS &
MUSCULOSKELETAL PATHOLOGIES
TO YOUR PORTFOLIO

1
Summary

• In India the market demand is growing 4

• Osteoarthritis is increasing due to the ageing of the

population 5

• A new growing middle class is willing to undergo

treatment 6

• Pharmacological treatments are increasingly effective

and efficient 7

• A safe and cutting-edge technology 8

2
Viscosupplementation is now the solution to treat patients
with osteoarthritis & MSK pathologies in the right way.

Today osteoarthritis constitutes the most common cause of

musculoskeletal disability across the globe. Over the last decade,
intra-articular viscosupplementation with hyaluronic acid has become
an increasingly accepted therapeutic alternative to joint replacement
surgery in the symptomatic management of osteoarthritis. India, and
in general the countries of the Asia-Pacific region, are playing a major
role in determining this worldwide trend.

A rising graph for the demand for viscosupplementation products is

promoting pharmaceutical markets and other associated business
sectors to meet their client base, which in turn is considered to
propose significant prospects in the market.

That’s why, in order to grow your business exponentially, you need

to include today a product for viscosupplementation to treat
osteoarthritis & MSK pathologies in your pharmaceutical catalogue.

Here, we have outlined five important reasons to make you realize the
vital importance of doing this.

3
1. IN INDIA THE MARKET DEMAND IS GROWING

The Indian demand for Viscosupplementation is growing

tremendously. When compared, the numbers indicate an increasing
trend. The Indian viscosupplementation market was worth $ 69.1
million in 2016 and this market is expected to grow at an annual rate
of 8.7% to reach $ 1.193 billion in 2027. India is in line with the other
APAC (Asia Pacific Region) countries where the viscosupplementation
market is growing at an annual rate of 8.7% and is expected to be
worth $1.193 billion in 2027 (Source: Coherent Market Insights).

4
2. O
 STEOARTHRITIS IS INCREASING DUE TO THE AGEING
OF THE POPULATION

Osteoarthritis is a degenerative disorder of joints, getting worse

with ageing, and if left untreated, the pain, swelling and discomfort
will get worse over time. Tragically, all over the world osteoarthritis
is increasing due to the ageing of the population. The target
of potential patients willing to try viscosupplementation is thus
expanding from year to year.
According to the 2011 census, the over 60 population in India showed
up ageing in 8.6% of the population. If this trend grows 3% annually,
the number will rise to 319 million in 2050. Older people demand safe
and budget-friendly clinical procedures, and this wave offers a higher
petition of hyaluronic acid viscosupplementation products in the
market.

5
3. A
 NEW GROWING MIDDLE CLASS IS WILLING
TO UNDERGO TREATMENT

Today, India is living through a period of great economic and social

change.
The upsurge of a new middle class tends to follow and undergo
healthcare tips as well as treatments as they are aware that
supplements and supplementation products work to revitalize life.
Urbanisation has created an ever-growing band of the population
eager to access health care and, in particular, to treatment for
osteoarthritis.

6
4. P
 HARMACOLOGICAL TREATMENTS ARE INCREASINGLY
EFFECTIVE AND EFFICIENT

In line with market demand, pharmacological treatments for

osteoarthritis are rapidly and effectively increasing. Today, when
suffering from osteoarthritis, current pharmacological treatments can
guarantee brilliant results in terms of efficacy.

Considering that in many cases OA is a condition treatable without

surgery, viscosupplementation with hyaluronic acid helps reprieving
and relieving pain in the joints even with a single injection. This
allows to minimize the risks of infection caused by the injections
themselves and by multiple rounds to the clinic.

Moreover, viscosupplementation with hyaluronic acid should not

only be considered as an alternative treatment in case of failure or
contraindications of NSAIDs, but instead a first-line & safe approach
to osteoarthritis for all the patients that need a restoration of the
physiological properties of the affected joints.

Helping to relieve the symptoms of osteoarthritis also for a long time,

viscosupplementation allows to avoid or postpone surgery.

7
Being practical and unfailing treatment, viscosupplementation is
being preferred by the geriatric population and hence by the Indian
pharmaceutical market in a growing trend.

5. A SAFE AND CUTTING-EDGE TECHNOLOGY

The IBSA hyaluronic acid contained in Sinovial® is a substitute for

synovial fluid and restores the physiological and rheological properties
of affected joints.

Sinovial® has a number of unique properties that make it a premium

product. It contains high-quality hyaluronic acid, highly concentrated
and viscous. It is produced with multiphase bio-fermentation,
not contaminated by products of animal origin (no risk of allergy
or transmission of any pathogens). Its effects are already evident
from the first injection and last up to 6 months, suggesting that the
treatment has a long-term carry-over effect. The latest born product
(Sinogel®) is enriched by the presence of chondroitin - a substance,
like hyaluronic acid, naturally present in the connective tissues of the
human body - in the highest percentage on the market today.

8
Given the exponential growth in demand in the Indian market and
the high quality of the formulations available, adding a premium
viscosupplementation product in your catalogue is today the
strategic choice needed to drive your turnover to another speed.

9
 IBSA is a leading brand in the world
of viscosupplementation products for
osteoarthritis & MSK pathologies.

The pharmaceutical company headquartered

in Switzerland offers the Indian market an
excellent product to meet the growing
domestic demand for viscosupplementation
solutions for osteoarthritis.

CONTACT US
for more information about this product

10
 ibsa.it
11